---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-000584"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:32:09.976570+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Chromocell launches eye pain program targeting $2.5B market; hires Dr. Simon Chandler

## Summary
- NaV1.7 sodium channel program for eye pain; addresses 5M annual U.S. corneal abrasions.
- Dr. Simon Chandler hired to lead program; 30+ years ophthalmic drug dev experience (Santen, Allergan).
- Program targets acute (corneal abrasion, glaucoma) and chronic (dry eye, neuropathic) indications.
- Company believes NaV1.7 platform can treat all eye pain indications, currently under-served.

## SEC filing metadata
- accession: 0001753926-24-000584
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392624000584/0001753926-24-000584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392624000584/g084141_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-000584
- JSON: https://secwatch.observer/filing/0001753926-24-000584.json
- Plain text: https://secwatch.observer/filing/0001753926-24-000584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.